With infections caused by the fungal pathogen Candida auris spreading at an “alarming rate” in the US, according to the Centers for Disease Control and Prevention
An FDA advisory committee has recommended approval of Cidara Therapeutics' once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caus
The EU regulator has started its review of Cidara Therapeutics' once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by
Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in t
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho